Marshall Wace’s Day One Biopharmaceuticals DAWN Stock Holding History

Marshall Wace’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-328,638	Closed	-$7.05M	–	3271
2026 Q1	$7.05M	Buy	+328,638	New	+$4.63M	0.01%	1134
2025 Q2	–	Sell	-887,177	Closed	-$7.04M	–	2796
2025 Q1	$7.04M	Sell	887,177 -210,585	-19%	-$2.27M	0.01%	910
2024 Q4	$13.9M	Buy	+1,097,762	New	+$15.3M	0.02%	675
2024 Q3	–	Sell	-161,129	Closed	-$2.22M	–	2588
2024 Q2	$2.22M	Buy	161,129 +26,958	+20%	+$394K	﹤0.01%	1313
2024 Q1	$2.22M	Buy	134,171 +16,277	+14%	+$244K	﹤0.01%	1316
2023 Q4	$1.72M	Sell	117,894 -343,941	-74%	-$4.17M	﹤0.01%	1284
2023 Q3	$5.67M	Sell	461,835 -327,797	-42%	-$4.28M	0.01%	828
2023 Q2	$9.43M	Buy	+789,632	New	+$10.3M	0.02%	760
2022 Q3	–	Sell	-145,898	Closed	-$2.61M	–	3415
2022 Q2	$2.61M	Buy	145,898 +128,155	+722%	+$1.32M	0.01%	1801
2022 Q1	$176K	Buy	+17,743	New	+$234K	﹤0.01%	3127

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's DAWN Position: Q2 2026 in Review

Marshall Wace sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 328,638 shares — an estimated $7.05M sold.

Marshall Wace first reported a position in DAWN in Q1 2022 and held it in 10 quarters. The position peaked at $13.9M in Q4 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Marshall Wace reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 328,638 Day One Biopharmaceuticals shares in Q2 2026, an estimated $7.05M.
Marshall Wace first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 10 quarters.
Marshall Wace's Day One Biopharmaceuticals position peaked at $13.9M in Q4 2024.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.